Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DANNY NGUYEN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1386960334
CMS profile
1289737
Location
HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$2,319.53

126 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,319.53 126

By paying entity

PY2020 · entire year · sorted by reported total

Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DANNY NGUYEN

NPI 1386960334 · CMS profile ID 1289737

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1386960334?year=2020&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DANNY NGUYEN, NPI 1386960334, CMS profile ID 1289737. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1386960334?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). DANNY NGUYEN, NPI 1386960334, CMS profile ID 1289737. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1386960334?year=2020&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
DANNY NGUYEN, NPI 1386960334, CMS profile ID 1289737, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–126 of 126 matching records. This page contains 26 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1386960334?year=2020&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

126 matching records · $2,319.53 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 126 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–126 of 126.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer HealthCare Pharmaceuticals Inc. $8.2503/11/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713646679 CMS
Daiichi Sankyo Inc. $20.3403/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 739489417 CMS
Bayer HealthCare Pharmaceuticals Inc. $21.2003/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713650413 CMS
Novartis Pharmaceuticals Corporation $22.1803/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726044407 CMS
Puma Biotechnology, Inc. $17.1303/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 750539469 CMS
Merck Sharp & Dohme Corporation $17.7103/04/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747748053 CMS
AbbVie Inc. $21.5503/03/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722053281 CMS
E.R. Squibb & Sons, L.L.C. $0.4402/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727939393 CMS
E.R. Squibb & Sons, L.L.C. $14.2202/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727939397 CMS
Janssen Biotech, Inc. $5.6702/28/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719096999 CMS
Pharmacyclics LLC, An AbbVie Company $22.4202/26/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 725661075 CMS
E.R. Squibb & Sons, L.L.C. $4.7502/25/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727939385 CMS
Celgene Corporation $24.6302/20/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727939537 CMS
Janssen Biotech, Inc. $24.6402/18/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719097019 CMS
Bayer HealthCare Pharmaceuticals Inc. $23.7402/13/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 713650855 CMS
Merck Sharp & Dohme Corporation $19.0002/10/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747743975 CMS
PFIZER INC. $19.2702/07/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743805733 CMS
Amgen Inc. $14.0001/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 740986059 CMS
Merck Sharp & Dohme Corporation $16.4701/30/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747689777 CMS
E.R. Squibb & Sons, L.L.C. $12.1101/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727939409 CMS
E.R. Squibb & Sons, L.L.C. $5.7401/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 727939413 CMS
Janssen Biotech, Inc. $28.5401/27/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 719097017 CMS
PFIZER INC. $14.2601/21/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743805731 CMS
Genentech USA, Inc. $20.8601/16/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 743001375 CMS
Merck Sharp & Dohme Corporation $17.5001/09/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 747644287 CMS
Novartis Pharmaceuticals Corporation $21.0401/06/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 726044400 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,401.32 144
PY2020 $2,319.53 126
PY2021 $1,694.67 75
PY2022 $409.44 11
PY2023 $2,680.85 21
PY2024 $10,335.84 20
PY2025 $10,849.67 22

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $1,270.00 2
PY2025 Principal investigator $502,885.25 29
PY2024 Recipient $330.00 1
PY2024 Principal investigator $549,646.29 45
PY2023 Recipient $13,291.75 1
PY2023 Principal investigator $1,136,523.44 54
PY2022 Principal investigator $293,203.69 28
PY2021 Principal investigator $718,530.34 69
PY2020 Principal investigator $560,473.06 69
PY2019 Principal investigator $750,922.75 62

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

31 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $2,718.00 12/22/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175440779
Principal investigator 1 Janssen Research & Development, LLC $15,908.00 12/22/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175440785
Principal investigator 1 Janssen Research & Development, LLC $9,557.00 12/22/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175440810
Principal investigator 1 Janssen Research & Development, LLC $2,750.00 12/04/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Metastatic Non-small Cell Lung Cancer After Progression on Osimertinib and Chemotherapy No dispute reported 06/30/2026 1175440849
Principal investigator 1 Janssen Research & Development, LLC $34,388.00 12/01/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175440766
Principal investigator 1 Janssen Research & Development, LLC $24,944.00 11/28/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175440405
Principal investigator 1 Janssen Research & Development, LLC $37,886.00 11/28/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175440492
Principal investigator 1 Janssen Research & Development, LLC $10,931.00 11/28/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175440714
Principal investigator 1 Janssen Research & Development, LLC $25,326.50 11/07/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175440444
Principal investigator 1 Janssen Research & Development, LLC $1,496.00 11/07/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175440703
Principal investigator 1 Janssen Research & Development, LLC $2,992.00 11/03/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175440684
Principal investigator 1 Janssen Research & Development, LLC $1,000.00 10/31/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175440244
Principal investigator 1 Janssen Research & Development, LLC $7,861.00 10/06/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1175440058
Principal investigator 1 Janssen Research & Development, LLC $22,673.00 09/01/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175440275
Principal investigator 1 Janssen Research & Development, LLC $35,401.00 09/01/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175440411
Principal investigator 1 Janssen Research & Development, LLC $4,264.00 09/01/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175440439
Principal investigator 1 Janssen Research & Development, LLC $39,163.00 09/01/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175440448
Principal investigator 1 Janssen Research & Development, LLC $5,414.00 09/01/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175440743
Principal investigator 1 Janssen Research & Development, LLC $26,632.00 07/28/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175440342
Principal investigator 1 Janssen Research & Development, LLC $51,500.00 07/25/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175440079
Principal investigator 1 Janssen Research & Development, LLC $9,286.00 07/22/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Loc No dispute reported 06/30/2026 1175440667
Principal investigator 1 Janssen Research & Development, LLC $17,012.00 07/21/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175440264
Principal investigator 1 Janssen Research & Development, LLC $296.00 07/07/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175440164
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $508.75 06/04/2025 Covered Recipient Teaching Hospital
CITY OF HOPE NATIONAL MEDICAL CTR
A RANDOMIZED PHASE 3 MULTICENTER OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF TAK-788 AS FIRST-LINE TREATMENT VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH NON-SMALL CELL LUNG CANCER WITH EGFR EXON 20 INSERTION MUTATIONS No dispute reported 06/30/2026 1223264928
Principal investigator 1 Janssen Research & Development, LLC $1,024.00 05/08/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175440604
Recipient PFIZER INC. $940.00 04/21/2025 Covered Recipient Physician TUCATINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228829009
Principal investigator 1 Janssen Research & Development, LLC $26,403.00 03/07/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175440516
Principal investigator 1 Janssen Research & Development, LLC $33,154.00 02/24/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Phase 3, Open-label, Randomized Study of Lazertinib with Subcutaneous Amivantamab Administered via Manual Injection Compared with Intravenous Amivantamab or Amivantamab Subcutaneous On Body Delivery System in Patients with EGFR-mutated Advanced or Meta No dispute reported 06/30/2026 1175440894
Recipient PFIZER INC. $330.00 02/11/2025 Covered Recipient Physician TUCATINIB CLINICAL PUBLICATION PROGRAM No dispute reported 06/30/2026 1228829068
Principal investigator 1 Janssen Research & Development, LLC $33,521.00 02/06/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175440035
Principal investigator 1 Janssen Research & Development, LLC $18,876.00 02/06/2025 Covered Recipient Teaching Hospital
City Of Hope National Medical Ctr
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non Small Cell Lung Cancer No dispute reported 06/30/2026 1175440152